IRME · As filed with the SEC
IR-Med income statement, by quarter
The statement as IR-Med presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Interim Condensed Consolidated Statements of Operations (Unaudited) · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q2 2025† 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q4 2023† 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Research and development expenses | ||||||
| Expenses incurred | 91 | 64 | 297† | 257 | 249 | 491† |
| Less- government grants | 0† | (41) | (81)† | (52) | (155) | — |
| Research and development expenses, net | 91 | 23 | 216† | 205 | 94 | 491† |
| Marketing Expense | 1 | 2 | (5)† | 29 | 28 | 191† |
| Selling, General and Administrative Expense | 194 | 228 | 113† | 367 | 236 | 580† |
| Total operating loss | 286 | 253 | 324† | 601 | 358 | 1,262† |
| Financial expenses, net | 415 | 520 | 2† | (3) | 8 | 9† |
| Loss for the period | 701 | 773 | 278† | 598 | 366 | 1,271† |
| Earnings Per Share (Basic) | (0.01) | (0.01) | — | (0.01) | (0.01) | — |
| Earnings Per Share (Diluted) | (0.01) | (0.01) | — | (0.01) | (0.01) | — |
| Weighted Average Shares Outstanding | 73,755,083 | — | — | 70,758,796 | 70,281,511 | — |
| Weighted Average Shares Outstanding, Diluted | 73,755,083 | — | — | 70,758,796 | 70,281,511 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.